Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Authors' conclusion
Higher adalimumab levels were associated with a better response and improved drug survival for all diagnoses, with a suggested lower threshold of 6.0 mg/l for RA/PsA.
Study context
- Population
- Patients with RA, PsA or axial SpA (axSpA) on adalimumab in the observational NOR-DMARD study
- Participants
- 340 patients
- Exposure
- RA vs PsA vs axSpA
- RAn = 97
- PsAn = 69
- axSpAn = 174
- Outcome
- Associations between serum adalimumab level, treatment response and drug survival
- Follow-up
- 3 months
Methodological detailsNOR-DMARD study, non-trough levels at 3 months
- NOR-DMARD study
- Non-trough levels at 3 months
Main finding
As reported in the abstract
Serum adalimumab level at 3 months
Median adalimumab level (IQR 4.0-10.3), all patients
7.3 mg/l
RA and PsA: adalimumab ≥6.0 mg/l and treatment response, OR
2.2
95% CI 1.0, 4.4
RA and PsA: adalimumab ≥6.0 mg/l and drug survival, HR
0.49
95% CI 0.27, 0.80
Observational data: associations, not effects.
Further findings
Anti-drug antibody (ADAb) formation
- Patients developing ADAbs
- 33 (10%)
- Associated factors: previous bDMARD use, no MTX comedication, adalimumab originator vs GP2017
Original publication
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases. Rheumatology (Oxford). Published 29 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →